Home Newsfeeds Alliance Global Partners Downgrades T2 Biosystems to Neutral

Alliance Global Partners Downgrades T2 Biosystems to Neutral

Alliance Global Partners analyst Ben Haynor downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Alliance Global Partners analyst Ben Haynor downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

Theriva Biologics To Discuss The Trial Design For VIRAGE – A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 25, 8:34 AM

Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength

TOVX

New York Community Bancorp Board Recommends Shareholders Vote For Proposal To Effect Reverse Stock Split By A Ratio Of 1-3, With Action To Be Effected At Such Time And Date As Determined By The Board, Within One Year After The Conclusion Of The 2024 An…

By Benzinga Newsdesk

April 25, 9:18 AM

PROPOSAL RECOMMENDATIONOF THE BOARD: Proposal 1The election of three directors to three-year terms. FOR ALL Proposal 2Ratification of

NYCB

Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $281

By Benzinga Newsdesk

December 12, 11:20 AM

Wells Fargo analyst Larry Biegelsen maintains Stryker (NYSE:SYK) with a Overweight and raises the price target from $248 to $281.

SYK

Alkaline Water Co Q1 Sales $15.00M Down From $16.89M YoY

By Benzinga Newsdesk

September 22, 1:06 PM

First Quarter of Fiscal 2024 Financial Performance (all amounts in U.S. dollars):Revenue: Down 8% Year-over-Year (YoY) to $15 MM.Gross Profit Margin: Improved by 733 basis points YoY to 25%.Total Operating Expenses

WTER

Alliance Global Partners Downgrades T2 Biosystems to Neutral

Related Posts

Theriva Biologics To Discuss The Trial Design For VIRAGE – A Phase 2b Clinical Study Of Systemically Administered VCN-01 In Combination With Chemotherapy In Pancreatic Ductal Adenocarcinoma At The 2024 ASCO Annual Meeting

New York Community Bancorp Board Recommends Shareholders Vote For Proposal To Effect Reverse Stock Split By A Ratio Of 1-3, With Action To Be Effected At Such Time And Date As Determined By The Board, Within One Year After The Conclusion Of The 2024 An…

Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $281

Alkaline Water Co Q1 Sales $15.00M Down From $16.89M YoY